AP230A - 3-(2-(dimethylamino) ethyl) -n-methyl 1h-indole-5-methane sulphonamide sulphate and pharmaceutical compositions thereof. - Google Patents

3-(2-(dimethylamino) ethyl) -n-methyl 1h-indole-5-methane sulphonamide sulphate and pharmaceutical compositions thereof. Download PDF

Info

Publication number
AP230A
AP230A APAP/P/1991/000339A AP9100339A AP230A AP 230 A AP230 A AP 230A AP 9100339 A AP9100339 A AP 9100339A AP 230 A AP230 A AP 230A
Authority
AP
ARIPO
Prior art keywords
salt
ethyl
dimethylamino
indole
physiologically acceptable
Prior art date
Application number
APAP/P/1991/000339A
Other languages
English (en)
Other versions
AP9100339A0 (en
Inventor
Joanne Graig
Derek Leslie Crookes
Stephen John Skittrall
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AP9100339A0 publication Critical patent/AP9100339A0/xx
Application granted granted Critical
Publication of AP230A publication Critical patent/AP230A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
APAP/P/1991/000339A 1990-12-12 1991-12-11 3-(2-(dimethylamino) ethyl) -n-methyl 1h-indole-5-methane sulphonamide sulphate and pharmaceutical compositions thereof. AP230A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments

Publications (2)

Publication Number Publication Date
AP9100339A0 AP9100339A0 (en) 1992-01-31
AP230A true AP230A (en) 1993-01-27

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1991/000339A AP230A (en) 1990-12-12 1991-12-11 3-(2-(dimethylamino) ethyl) -n-methyl 1h-indole-5-methane sulphonamide sulphate and pharmaceutical compositions thereof.

Country Status (36)

Country Link
US (2) US5554639A (is)
EP (1) EP0490689B1 (is)
JP (1) JP2994037B2 (is)
KR (1) KR100211479B1 (is)
CN (2) CN1030890C (is)
AP (1) AP230A (is)
AT (1) ATE119881T1 (is)
AU (1) AU650706B2 (is)
BE (1) BE1005085A3 (is)
CA (1) CA2098302C (is)
CH (1) CH684192A5 (is)
CY (1) CY2005A (is)
CZ (1) CZ281931B6 (is)
DE (1) DE69108200T2 (is)
DK (1) DK0490689T3 (is)
EG (1) EG20219A (is)
ES (1) ES2069836T3 (is)
FR (1) FR2670487B1 (is)
GB (2) GB9026998D0 (is)
GR (1) GR3015430T3 (is)
HK (1) HK82697A (is)
HU (1) HU211937A9 (is)
IE (1) IE62894B1 (is)
IL (1) IL100330A (is)
IS (1) IS1706B (is)
IT (1) IT1252868B (is)
MX (1) MX9102501A (is)
MY (1) MY109265A (is)
NL (1) NL9102071A (is)
NZ (1) NZ240942A (is)
PT (1) PT99757B (is)
RU (1) RU2108328C1 (is)
TW (2) TW205035B (is)
WO (1) WO1992010477A1 (is)
YU (1) YU48926B (is)
ZA (1) ZA919750B (is)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0573221B1 (en) * 1992-06-05 1998-04-29 Merck Sharp & Dohme Ltd. The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132757A (en) 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6562838B2 (en) 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
DK1435945T3 (da) * 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
CA2509023C (en) * 2002-12-26 2011-05-24 Pozen Inc. Multilayer dosage forms containing nsaids and triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
WO2004112723A2 (en) * 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
WO2005119607A2 (en) * 2004-06-03 2005-12-15 Tyfone, Inc. System and method for securing financial transactions
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
AU2007310949A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
EP2297141B1 (en) 2008-05-27 2015-10-21 Biota Scientific Management Pty Ltd Antiviral salts
US8618157B2 (en) * 2008-06-20 2013-12-31 Alphapharm Pty. Ltd. Pharmaceutical formulation
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
AU2009269129B2 (en) * 2008-06-30 2015-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US9211282B2 (en) 2009-09-25 2015-12-15 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
CN107530318A (zh) 2015-03-02 2018-01-02 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
ES2842523T3 (es) 2015-05-15 2021-07-14 Univ Michigan Regents Métodos y composiciones para el tratamiento de la artritis
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
CN117304172A (zh) 2017-11-07 2023-12-29 密执安大学评议会 化合物、药物组合物、其制备方法以及治疗疾病的方法
WO2020049523A1 (en) 2018-09-07 2020-03-12 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
AU2021227937A1 (en) * 2020-02-27 2022-09-08 Biohaven Pharmaceutical Holding Company Ltd. Oral fast-dispersing dosage form of rimegepant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522A (en) * 1984-08-01 1986-02-05 Glaxo Group Ltd An indole derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522A (en) * 1984-08-01 1986-02-05 Glaxo Group Ltd An indole derivative

Also Published As

Publication number Publication date
US5554639A (en) 1996-09-10
AP9100339A0 (en) 1992-01-31
GB2251614A (en) 1992-07-15
DE69108200T2 (de) 1995-07-20
KR100211479B1 (ko) 1999-08-02
CN1050831C (zh) 2000-03-29
NZ240942A (en) 1994-03-25
EP0490689B1 (en) 1995-03-15
PT99757A (pt) 1992-12-31
IS1706B (is) 1998-12-10
GB9026998D0 (en) 1991-01-30
ITRM910922A0 (it) 1991-12-11
CN1030890C (zh) 1996-02-07
DK0490689T3 (da) 1995-05-22
BE1005085A3 (fr) 1993-04-13
JPH06503560A (ja) 1994-04-21
PT99757B (pt) 1999-05-31
AU650706B2 (en) 1994-06-30
AU9072091A (en) 1992-07-08
TW300886B (is) 1997-03-21
CA2098302C (en) 2001-10-16
CN1128259A (zh) 1996-08-07
GR3015430T3 (en) 1995-06-30
CA2098302A1 (en) 1992-06-13
EG20219A (en) 1997-11-30
IL100330A0 (en) 1992-09-06
EP0490689A1 (en) 1992-06-17
TW205035B (is) 1993-05-01
RU2108328C1 (ru) 1998-04-10
IT1252868B (it) 1995-06-28
IL100330A (en) 1996-06-18
YU48926B (sh) 2002-12-10
GB2251614B (en) 1994-12-14
MX9102501A (es) 1992-09-01
YU191491A (sh) 1994-04-05
ZA919750B (en) 1992-10-28
WO1992010477A1 (en) 1992-06-25
CH684192A5 (fr) 1994-07-29
ITRM910922A1 (it) 1993-06-11
DE69108200D1 (de) 1995-04-20
CN1063099A (zh) 1992-07-29
ES2069836T3 (es) 1995-05-16
MY109265A (en) 1996-12-31
US5705520A (en) 1998-01-06
GB9126297D0 (en) 1992-02-12
FR2670487B1 (fr) 1993-08-20
CZ114093A3 (en) 1994-02-16
IE62894B1 (en) 1995-03-08
FR2670487A1 (fr) 1992-06-19
HU211937A9 (en) 1996-01-29
IS3790A7 (is) 1992-06-13
HK82697A (en) 1997-06-27
IE914317A1 (en) 1992-06-17
CY2005A (en) 1997-12-05
CZ281931B6 (cs) 1997-04-16
ATE119881T1 (de) 1995-04-15
NL9102071A (nl) 1992-07-01
JP2994037B2 (ja) 1999-12-27

Similar Documents

Publication Publication Date Title
AP230A (en) 3-(2-(dimethylamino) ethyl) -n-methyl 1h-indole-5-methane sulphonamide sulphate and pharmaceutical compositions thereof.
US5393773A (en) Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide
US6740306B2 (en) Imidazotriazinone-containing compositions for nasal administration
RU2130022C1 (ru) N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство
US7576133B2 (en) Methods and compositions for nasal administration of modafinil
US5834502A (en) Triazolylmethyl-indole ethylamine bisulfate salt
EP0840733B1 (en) A triazolylmethyl-indole ethylamine bisulfate salt
NO179102B (no) 3-[2-(dimetylamino)etylÅ-N-metyl-1H-indol-5-metansulfonamid